The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]
Eric Siemers, MD
Advertisement
Chief medical officer at Acumen Pharmaceuticals.
Articles by Eric Siemers, MD
Advertisement
Latest Updated Articles
Advances in Alzheimer Disease Screening and Antibody Therapy at AAIC 2025: Eric Siemers, MDPublished: August 13th 2025 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Clene to Submit Application for CNM-Au8 as Potential ALS Treatment
2
Overview and Design of the OCEANIC-STROKE Trial
3
This Week on NeurologyLive® — November 17, 2025
4
Multidisciplinary Care Paths That Improve Neurosarcoidosis Management
5
